Literature DB >> 11444965

Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition-state analogue and dissection by parts.

L A Basso1, D S Santos, W Shi, R H Furneaux, P C Tyler, V L Schramm, J S Blanchard.   

Abstract

Purine salvage pathways are predicted to be present from the genome sequence of Mycobacterium tuberculosis. The M. tuberculosis deoD gene encodes a presumptive purine nucleoside phosphorylase (PNP). The gene was cloned, expressed, purified, and found to exhibit PNP activity. Purified M. tuberculosis PNP is trimeric, similar to mammalian PNP's but unlike the hexameric Escherichia coli enzyme. Immucillin-H is a rationally designed analogue of the transition state that has been shown to be a potent inhibitor of mammalian PNP's. This inhibitor also exhibits slow-onset inhibition of M. tuberculosis PNP with a rapid, reversible inhibitor binding (K(i) of 2.2 nM) followed by an overall dissociation constant (K(i)) of 28 pM, yielding a K(m)/K(i) value of 10(6). Time-dependent tight binding of the inhibitor occurs with a rate of 0.1 s(-)(1), while relaxation of the complex is slower at 1.4 x 10(-)(3) s(-)(1). The pH dependence of the K(i) value of immucillin-H to the M. tuberculosis PNP suggests that the inhibitor binds as the neutral, unprotonated form that is subsequently protonated to generate the tight-binding species. The M. tuberculosis enzyme demonstrates independent and equivalent binding of immucilin-H at each of the three catalytic sites, unlike mammalian PNP. Analysis of the components of immucillin-H confirms that the inhibition gains most of its binding energy from the 9-deazahypoxanthine group (K(is) of 0.39 microM) while the 1,4-dideoxy-1,4-iminoribitol binds weakly (K(is) of 2.9 mM). Double-inhibition studies demonstrate antagonistic binding of 9-deazahypoxanthine and iminoribitol (beta = 13). However, the covalent attachment of these two components in immucillin-H increases equilibrium binding affinity by a factor of >14 000 (28 pM vs 0.39 microM) compared to 9-deazahypoxanthine alone, and by a factor of >10(8) compared to iminoribitol alone (28 pM vs 2.9 mM), from initial velocity measurements. The structural basis for M. tuberculosis PNP inhibition by immucillin-H and by its component parts is reported in the following paper [Shi, W., Basso, L. A., Santos, D. S., Tyler, P. C., Furneaux, R. H., Blanchard, J. S., Almo, S. C., and Schramm, V. L. (2001) Biochemistry 40, 8204-8215].

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444965     DOI: 10.1021/bi010584x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Putative vaccine candidates and drug targets identified by reverse vaccinology and subtractive genomics approaches to control Haemophilus ducreyi, the causative agent of chancroid.

Authors:  Alissa de Sarom; Arun Kumar Jaiswal; Sandeep Tiwari; Letícia de Castro Oliveira; Debmalya Barh; Vasco Azevedo; Carlo Jose Oliveira; Siomar de Castro Soares
Journal:  J R Soc Interface       Date:  2018-05       Impact factor: 4.118

2.  6-Oxo and 6-thio purine analogs as antimycobacterial agents.

Authors:  Ashish K Pathak; Vibha Pathak; Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2013-02-04       Impact factor: 3.641

3.  Synthesis and evaluation of eight- and four-membered iminosugar analogues as inhibitors of testicular ceramide-specific glucosyltransferase, testicular β-glucosidase 2, and other glycosidases.

Authors:  Jae Chul Lee; Subhashree Francis; Dinah Dutta; Vijayalaxmi Gupta; Yan Yang; Jin-Yi Zhu; Joseph S Tash; Ernst Schönbrunn; Gunda I Georg
Journal:  J Org Chem       Date:  2012-03-20       Impact factor: 4.354

4.  Identification and characterization of two adenosine phosphorylase activities in Mycobacterium smegmatis.

Authors:  Kajal Buckoreelall; Landon Wilson; William B Parker
Journal:  J Bacteriol       Date:  2011-08-05       Impact factor: 3.490

5.  Crystallization and preliminary X-ray diffraction analysis of prephenate dehydratase from Mycobacterium tuberculosis H37Rv.

Authors:  Ana Luiza Vivan; Márcio Vinícius Bertacini Dias; Cristopher Z Schneider; Walter Filgueira de Azevedo; Luiz Augusto Basso; Diógenes Santiago Santos
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-03-10

6.  Identification and characterization of a unique adenosine kinase from Mycobacterium tuberculosis.

Authors:  Mary C Long; Vincent Escuyer; William B Parker
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

7.  New Insights into Active Site Conformation Dynamics of E. coli PNP Revealed by Combined H/D Exchange Approach and Molecular Dynamics Simulations.

Authors:  Saša Kazazić; Branimir Bertoša; Marija Luić; Goran Mikleušević; Krzysztof Tarnowski; Michal Dadlez; Marta Narczyk; Agnieszka Bzowska
Journal:  J Am Soc Mass Spectrom       Date:  2015-09-03       Impact factor: 3.109

8.  Substrate deconstruction and the nonadditivity of enzyme recognition.

Authors:  Sarah Barelier; Jennifer A Cummings; Alissa M Rauwerdink; Daniel S Hitchcock; Jeremiah D Farelli; Steven C Almo; Frank M Raushel; Karen N Allen; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2014-05-12       Impact factor: 15.419

9.  The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.

Authors:  Vinayak Singh; Stefano Donini; Angela Pacitto; Claudia Sala; Ruben C Hartkoorn; Neeraj Dhar; Gyorgy Keri; David B Ascher; Guillaume Mondésert; Anthony Vocat; Andréanne Lupien; Raphael Sommer; Hélène Vermet; Sophie Lagrange; Joe Buechler; Digby F Warner; John D McKinney; Janos Pato; Stewart T Cole; Tom L Blundell; Menico Rizzi; Valerie Mizrahi
Journal:  ACS Infect Dis       Date:  2016-09-08       Impact factor: 5.084

10.  Insights into phosphate cooperativity and influence of substrate modifications on binding and catalysis of hexameric purine nucleoside phosphorylases.

Authors:  Priscila O de Giuseppe; Nadia H Martins; Andreia N Meza; Camila R dos Santos; Humberto D'Muniz Pereira; Mario T Murakami
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.